Page last updated: 2024-10-30

metformin and Bacteriuria

metformin has been researched along with Bacteriuria in 1 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Bacteriuria: The presence of bacteria in the urine which is normally bacteria-free. These bacteria are from the URINARY TRACT and are not contaminants of the surrounding tissues. Bacteriuria can be symptomatic or asymptomatic. Significant bacteriuria is an indicator of urinary tract infection.

Research Excerpts

ExcerptRelevanceReference
"To examine the effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor that lowers blood glucose by increasing urinary glucose excretion (UGE), on asymptomatic bacteriuria and urinary tract infections (UTIs)."9.16Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. ( Capuano, G; Nicolle, LE; Usiskin, K; Ways, K, 2012)
"To examine the effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor that lowers blood glucose by increasing urinary glucose excretion (UGE), on asymptomatic bacteriuria and urinary tract infections (UTIs)."5.16Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. ( Capuano, G; Nicolle, LE; Usiskin, K; Ways, K, 2012)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nicolle, LE1
Capuano, G1
Ways, K1
Usiskin, K1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 [NCT00642278]Phase 2451 participants (Actual)Interventional2008-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Absolute Change in Body Weight From Baseline to Week 12

The table below shows the mean absolute change in body weight from Baseline to Week 12 for each treatment group. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12

Interventionkg (Mean)
Placebo-0.78
Canagliflozin 50 mg Daily-1.96
Canagliflozin 100 mg Daily-2.25
Canagliflozin 200 mg Daily-2.32
Canagliflozin 300 mg Daily-2.88
Canagliflozin 300 mg Twice Daily-2.87
Sitagliptin 100 mg Daily-0.43

Change in Fasting Plasma Glucose (FPG) From Baseline to Week 12

The table below shows the mean change in FPG from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12

Interventionmmol/L (Mean)
Placebo0.2
Canagliflozin 50 mg Daily-0.9
Canagliflozin 100 mg Daily-1.4
Canagliflozin 200 mg Daily-1.5
Canagliflozin 300 mg Daily-1.4
Canagliflozin 300 mg Twice Daily-1.3
Sitagliptin 100 mg Daily-0.7

Change in HbA1c From Baseline to Week 12

The table below shows the mean change in HbA1c from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12

InterventionPercent (Mean)
Placebo-0.22
Canagliflozin 50 mg Daily-0.79
Canagliflozin 100 mg Daily-0.76
Canagliflozin 200 mg Daily-0.70
Canagliflozin 300 mg Daily-0.92
Canagliflozin 300 mg Twice Daily-0.95
Sitagliptin 100 mg Daily-0.74

Change in Overnight Urine Glucose/Creatinine Ratio From Baseline to Week 12

The table below shows the mean change in overnight urine glucose/creatinine ratio from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12

Interventionmg/mg (Mean)
Placebo1.9
Canagliflozin 50 mg Daily35.4
Canagliflozin 100 mg Daily51.5
Canagliflozin 200 mg Daily50.5
Canagliflozin 300 mg Daily49.4
Canagliflozin 300 mg Twice Daily61.6
Sitagliptin 100 mg Daily-1.9

Percent Change in Body Weight From Baseline to Week 12

The table below shows the mean percent change in body weight from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12

InterventionPercent change (Mean)
Placebo-1.1
Canagliflozin 50 mg Daily-2.3
Canagliflozin 100 mg Daily-2.6
Canagliflozin 200 mg Daily-2.7
Canagliflozin 300 mg Daily-3.4
Canagliflozin 300 mg Twice Daily-3.4
Sitagliptin 100 mg Daily-0.6

Percentage of Patients With Symptoms of Hypoglycemia

The table below shows the percentage of patients who experienced symptomatic hypoglycemic events between Baseline and Week 12. (NCT00642278)
Timeframe: Up to Week 12

InterventionPercentage of patients (Number)
Placebo2
Canagliflozin 50 mg Daily0
Canagliflozin 100 mg Daily2
Canagliflozin 200 mg Daily6
Canagliflozin 300 mg Daily0
Canagliflozin 300 mg Twice Daily3
Sitagliptin 100 mg Daily5

Trials

1 trial available for metformin and Bacteriuria

ArticleYear
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
    Current medical research and opinion, 2012, Volume: 28, Issue:7

    Topics: Bacteriuria; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G

2012
chemdatabank.com